Stiefel, Basilea sign agreement for Toctino
Toctino is used to treat adults with severe chronic hand eczema that is refractory to treatment with potent topical corticosteroids. Under the agreement Stiefel will be responsible for
Teva Pharmaceuticals International and Polpharma Biologics have signed a global licensing agreement for a proposed biosimilar to Ocrevus (ocrelizumab) to treat multiple sclerosis (MS).
The research collaboration will focus on three neglected tropical diseases (NTDs), leishmaniasis, Chagas disease, and sleeping sickness. Astellas drug discovery research senior vice president Shin-ichi Tsukamoto said the